ପିତ୍ତନଳୀ କର୍କଟ
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
କେଉଁଠିକୁ ଯିବେ
ଭାରତର 4 ଟି ହସ୍ପିଟାଲ ଏହି ଟ୍ରାଏଲ୍ ପାଇଁ ରୋଗୀଙ୍କୁ ନେଉଛନ୍ତି.
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
ସ୍ପୋନ୍ସର: ଜାଜ୍ ଫାର୍ମାସ୍ୟୁଟିକାଲ୍ସ
କ୍ଲିନିକାଲ୍ ଟ୍ରାଏଲ୍ସ.ଗଭ୍ (ClinicalTrials.gov) ରେ NCT06282575
ରେଜିଷ୍ଟ୍ରିରେ ଶେଷ ଅପଡେଟ୍ ୧୪ ସେପ୍ଟେମ୍ବର ୨୦୨୬ · ଆମେ ପଢିଲୁ ୨୦ ଅକ୍ଟୋବର ୨୦୨୬